Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: a new class of anti-HIV agents (Q28376396)

2

0 references

T Katsube

3

0 references

T Kimura

4

0 references

T Komai

5

0 references

K Momota

6

0 references

T Ohmine

7

0 references

T Nishigaki

8

0 references

S Kimura

9

0 references

K Shimada

Bioorganic & Medicinal Chemistry Letters

10

0 references

language of work or name

English

0 references

publication date

1 November 1999

0 references

published in

0 references

volume

9

0 references

issue

21

0 references

page(s)

3063-8

0 references

cites work

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Decline in deaths from AIDS due to new antiretrovirals

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021

Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2899%2900537-5

7 January 2021